Physician profile
Timothy E Peterson
NPI 1922362490
$844.87
in general payments reported to CMS, 2019-2025
14 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.94 · 2020: $14.12 · 2021: $44.78 · 2022: $254 · 2023: $225 · 2024: $175 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $177.40 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $172.94 | 2020-2024 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.32 | 2022-2023 | Jardiance |
| Abbvie INC. | $75.25 | 2021-2025 | |
| Lilly USA, LLC | $71.61 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $47.38 | 2023-2024 | |
| Novo Nordisk INC | $44.66 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $37.20 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Inspire Medical Systems, INC. | $33.35 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $30.14 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.41 | 2023 | |
| Lundbeck LLC | $20.03 | 2023 | Vyepti |
| Radius Health, INC. | $16.86 | 2024 | Tymlos |
| Phathom Pharmaceuticals, INC. | $13.32 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.